Grace Therapeutics Reports Q2 GAAP EPS of -$0.11, Exceeding Estimates
Grace Therapeutics (GRCE) reported second-quarter GAAP earnings per share of -$0.11, which outperformed market expectations by $0.04. The results indicate a narrower-than-anticipated loss for the period. The company also demonstrated improved liquidity during the quarter. As of September 30, 2026, cash and cash equivalents rose to $21.3 million, representing a net increase of $4.3 million from the $17.0 million reported at the end of March 2026.
Topics: cash flow earnings beat GAAP EPS